BOCA RATON, Fla. — October 30, 2025 — Leads & Copy — INmune Bio Inc. (NASDAQ: INMB) has announced its financial results for the quarter ended September 30, 2025, along with a business update.
Key highlights include the successful completion of the first two commercial pilot-scale manufacturing runs of CORDStrom™ at CGT Catapult, in preparation for regulatory filings to seek approval for recessive dystrophic epidermolysis bullosa (RDEB). The company anticipates an MAA submission mid-2026, followed by a BLA filing with the FDA. A manuscript on XPro1595 in early Alzheimer’s Disease with Inflammation (ADi) has been submitted for peer review, with data showing enhanced therapeutic benefits in dose-compliant participants. INKmune® platform analysis showed the CARE-PC trial met its primary endpoint and two secondary endpoints, with final data analysis expected in Q4 2026.
Financially, the net loss attributable to common stockholders for the quarter ended September 30, 2025, was approximately $6.5 million, compared to $12.1 million in the same period of 2024. As of September 30, 2025, the company had cash and cash equivalents of approximately $27.7 million. Upcoming events include additional CORDStrom™ data and imaging data from the phase 2 MINDFuL trial in Alzheimer’s Disease, both expected in Q4 2025, along with final data on the INKmune CARE-PC trial.
The company also announced the retirement of Dr. RJ Tesi and the appointment of David Moss as President & Chief Executive Officer, and Cory Ellspermann as CFO. Kelly Ganjei has been named Chairman of the board of directors.
Company Contact:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Source: INmune Bio Inc.
